Bureaucrats, editor, reviewer, Administrators
2,392
edits
ALLHAT: Difference between revisions
Jump to navigation
Jump to search
no edit summary
(Created page with "{{info | title=FullTitleOfJournalArticle | abbreviation=CatchyAbbreviationThatIsCommonlyUsedAsAShorthand | expansion=WhatTheAbbreviationStandsForBecauseItMayNotBeTheSameAsTheJour...") |
No edit summary |
||
| Line 1: | Line 1: | ||
{{info | {{info | ||
| title= | | title=Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic | ||
| abbreviation= | | abbreviation=ALLHAT | ||
| expansion= | | expansion=The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial | ||
| published= | | published=2002-12-18 | ||
| author= | | author=ALLHAT Collaborative Research Group | ||
| journal= | | journal=The Journal of the American Medical Association | ||
| year= | | year=2002 | ||
| volume= | | volume=288 | ||
| issue= | | issue=23 | ||
| pages= | | pages=2981-2997 | ||
| pmid= | | pmid= 12479763 | ||
| fulltexturl= | | fulltexturl=http://jama.ama-assn.org/content/288/23/2981.long | ||
| pdfurl= | | pdfurl=http://jama.ama-assn.org/content/288/23/2981.full.pdf | ||
| status= | | status=Incomplete | ||
| subspecialty= | | subspecialty=Nephrology | ||
| otherSubspecialty1= | | otherSubspecialty1=Cardiology | ||
| disease=Hypertension | |||
| disease= | | briefDesignDescription=Chlorthalidone vs. amlodipine vs lisinopril | ||
| briefResultsDescription=Chlorthalidone is superior | |||
| trainingLevel=Medical Student | |||
| briefDesignDescription= | |||
| briefResultsDescription= | |||
| trainingLevel= | |||
}} | }} | ||
==Purpose== | ==Purpose== | ||
To compare therapy with a calcium channel blocker, ACE-inhibitor, or diuretic in lowering the incidence of CV events. | |||
==Major points== | ==Major points== | ||
According to ALLHAT, chlorthalidone was superior in preventing cardiovascular events, and it is preferred as the first-line agent in hypertension. | |||
==Design== | ==Design== | ||
* | * Randomized, double-blind, clinical trial conducted from February 1994 through March 2002. | ||
* N=33,357 randomly assigned to: chlorthalidone (n=15255); amlodipine (n=9048); or lisinopril (n=9054) | |||
* | * Mean follow-up: 4.9 years | ||
* | * Intent-to-treat analysis | ||
* | |||
==Enrollment criteria== | ==Enrollment criteria== | ||
===Inclusion criteria=== | ===Inclusion criteria=== | ||
* | * | ||
===Exclusion criteria=== | ===Exclusion criteria=== | ||
| Line 49: | Line 46: | ||
==Measured outcomes and results== | ==Measured outcomes and results== | ||
===Primary outcomes=== | ===Primary outcomes=== | ||
* | * Combined fatal coronary heart disease (CHD) or non-fatal MI | ||
===Secondary outcomes=== | ===Secondary outcomes=== | ||
* | * All-cause mortality | ||
* Stroke | |||
* Combined CHD (primary outcome, coronary revascularization, or angina with hospitalization) | |||
* Combined CVD (combined CHD, stroke, treated angina without hospitalization, HF, and peripheral arterial disease) | |||
===Subgroup analysis=== | ===Subgroup analysis=== | ||